BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 13, 2006
View Archived Issues
Human opiorphin potentiates analgesic effects of enkephalins by inhibiting their degradation
Read More
Calpain inhibitor delays disease severity and progression in a mouse model of multiple sclerosis
Read More
SF-1126 shows activity against multiple myeloma in preclinical studies
Read More
Aurora kinase inhibitor AZD-1152 blocks engraftment of AML tumors in vivo
Read More
NVP-TAE226 active against multiple myeloma in preclinical studies
Read More
YM-150: favorable biochemical and pharmacological profile reported
Read More
Targeting ALK with TAE-684 shows benefit in murine models of lymphoma
Read More
Fibrin Patch begins clinical studies
Read More
Allon cleared to begin phase II study of AL-108 in mild cognitive impairment
Read More
BioCancell advances development of BC-819 for metastatic liver cancer
Read More
NB-S101 studied in phase II trial for osteoporosis
Read More
Cell Therapeutics to close PIONEER study of Xyotax, new trial planned
Read More
V-24343 begins phase I trial for obesity and type 2 diabetes
Read More
elbion merges with 4AZA Bioscience
Read More
Actelion-1 enters phase III for pulmonary hypertension
Read More
GSK to acquire Domantis
Read More
Dynavax studies TLR9 agonist with chemotherapy for metastatic colorectal cancer
Read More
New agents for urinary incontinence emerge from Astellas Pharma R&D
Read More
SLV-319 begins phase IIb study for obesity
Read More
Encysive cleared to resume clinical studies with TBC-3711
Read More
Recent patents report novel analgesic agents
Read More
ReGen explores effects of zolpidem in people with brain damage
Read More
DIAS-2 stroke study of desmoteplase completes enrollment
Read More
TRO-19622 successfully completes phase Ib studies
Read More
Clinical hold lifted on MEM-3454
Read More
Recent patents disclose new therapeutic agents for anxiety, depression, etc.
Read More
Pafuramidine studied in phase II trial for prevention of malaria infection
Read More
Cintredekin besudotox not superior to Gliadel Wafer in phase III trial
Read More
1-TDC to begin pre-IND studies
Read More
New Rebif formulation studied in phase III
Read More
Idraparinux shows encouraging results in patients at high risk of thromboembolism
Read More
Xelox meets primary endpoint in phase III advanced colorectal cancer study
Read More
Phase III trials of alfimeprase in PAO and catheter occlusion fail to meet endpoints
Read More
Tasigna achieves impressive response rates in Glivec-resistant Ph+ CML patients
Read More